Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Rating of “Moderate Buy” by Brokerages

Esperion Therapeutics, Inc. (NASDAQ:ESPR) has received a consensus recommendation of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $6.42.

Several equities research analysts have issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 price target on shares of Esperion Therapeutics in a research note on Friday. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research report on Friday. JMP Securities reiterated a “market outperform” rating and issued a $4.00 price target (down from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. Finally, The Goldman Sachs Group decreased their price objective on Esperion Therapeutics from $4.00 to $3.00 and set a “neutral” rating on the stock in a report on Thursday, April 17th.

Hedge Funds Weigh In On Esperion Therapeutics

A number of hedge funds have recently made changes to their positions in ESPR. Summit Financial LLC increased its stake in Esperion Therapeutics by 18.2% during the fourth quarter. Summit Financial LLC now owns 46,528 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 7,150 shares during the last quarter. Foundations Investment Advisors LLC grew its holdings in shares of Esperion Therapeutics by 48.6% during the 4th quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 9,872 shares during the period. Invesco Ltd. increased its position in Esperion Therapeutics by 15.5% during the 4th quarter. Invesco Ltd. now owns 97,833 shares of the biopharmaceutical company’s stock worth $215,000 after purchasing an additional 13,101 shares in the last quarter. Two Sigma Advisers LP raised its holdings in Esperion Therapeutics by 0.4% in the fourth quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock valued at $7,956,000 after buying an additional 16,100 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its position in Esperion Therapeutics by 15.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 123,896 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 16,404 shares in the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Stock Up 4.4 %

ESPR opened at $0.92 on Tuesday. The firm has a market cap of $182.02 million, a P/E ratio of -1.44 and a beta of 0.86. The business’s fifty day simple moving average is $1.40 and its 200 day simple moving average is $1.96. Esperion Therapeutics has a 52 week low of $0.82 and a 52 week high of $3.94.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.